Skip to main content
Top
Published in: Digestive Diseases and Sciences 9/2015

01-09-2015 | Editorial

Ischemia/Reperfusion Injury and Hepatocellular Carcinoma Recurrence After Liver Transplantation: Cancer at WIT’s End?

Authors: Adrian H. Cotterell, Robert A. Fisher

Published in: Digestive Diseases and Sciences | Issue 9/2015

Login to get access

Excerpt

Hepatocellular carcinoma (HCC) is the second most common cause of cancer deaths worldwide, with hepatitis B representing its major risk factor. In the Western world, the risk factors have included infection with the more prevalent hepatitis C virus and alcoholic cirrhosis. With effective therapy for hepatitis C now available and with the obesity epidemic on the rise, the relative contribution of nonalcoholic steatohepatitis (NASH) to the incidence of HCC will undoubtedly increase. …
Literature
1.
go back to reference Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–699.CrossRefPubMed Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–699.CrossRefPubMed
2.
go back to reference Ramanathan R, Sharma A, Lee DD, et al. Multimodality therapy and liver transplantation for hepatocellular carcinoma: a 14-year prospective analysis of outcomes. Transplantation. 2014;98:100–106.PubMedCentralCrossRefPubMed Ramanathan R, Sharma A, Lee DD, et al. Multimodality therapy and liver transplantation for hepatocellular carcinoma: a 14-year prospective analysis of outcomes. Transplantation. 2014;98:100–106.PubMedCentralCrossRefPubMed
3.
go back to reference Kornberg A, Witt U, Kornberg J, et al. Extended ischemia times promote risk of HCC recurrence in liver transplant patients. Dig Dis Sci. (Epub ahead of print). doi:10.1007/s10620-015-3541-z. Kornberg A, Witt U, Kornberg J, et al. Extended ischemia times promote risk of HCC recurrence in liver transplant patients. Dig Dis Sci. (Epub ahead of print). doi:10.​1007/​s10620-015-3541-z.
4.
go back to reference Hsu C, Liu P, Lee Y, et al. Using serum α-fetoprotein for prognostic prediction in patients with hepatocellular carcinoma: what is the most optimal cutoff? PLoS One. 2015;10:e0118825. Hsu C, Liu P, Lee Y, et al. Using serum α-fetoprotein for prognostic prediction in patients with hepatocellular carcinoma: what is the most optimal cutoff? PLoS One. 2015;10:e0118825.
5.
go back to reference Lee S, Kim S, Kim S, et al. Clinical impact of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in living donor liver transplantation for advanced hepatocellular carcinoma. Transplantation. 2015. doi:10.1097/TP.0000000000000719. Lee S, Kim S, Kim S, et al. Clinical impact of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in living donor liver transplantation for advanced hepatocellular carcinoma. Transplantation. 2015. doi:10.​1097/​TP.​0000000000000719​.
6.
go back to reference Nagai S, Yoshida A, Facciuto M, et al. Ischemia time impacts recurrence of hepatocellular carcinoma after liver transplantation. Hepatology. 2015;61:895–904.CrossRefPubMed Nagai S, Yoshida A, Facciuto M, et al. Ischemia time impacts recurrence of hepatocellular carcinoma after liver transplantation. Hepatology. 2015;61:895–904.CrossRefPubMed
7.
go back to reference Zhai Y, Petrowsky H, Hong J, et al. Ischemia–reperfusion injury in liver transplantation—from bench to bedside. Nat Rev Gastroenterol Hepatol. 2013;10:79–89.PubMedCentralCrossRefPubMed Zhai Y, Petrowsky H, Hong J, et al. Ischemia–reperfusion injury in liver transplantation—from bench to bedside. Nat Rev Gastroenterol Hepatol. 2013;10:79–89.PubMedCentralCrossRefPubMed
8.
go back to reference Rao J, Yue S, Fu Y, et al. ATF6 mediates a pro-inflammatory synergy between ER stress and TLR activation in the pathogenesis of liver ischemia–reperfusion injury. Am J Transplant. 2014;14:1552–1561.PubMedCentralCrossRefPubMed Rao J, Yue S, Fu Y, et al. ATF6 mediates a pro-inflammatory synergy between ER stress and TLR activation in the pathogenesis of liver ischemia–reperfusion injury. Am J Transplant. 2014;14:1552–1561.PubMedCentralCrossRefPubMed
9.
go back to reference Dubois-Pot-Schneider H, Fekir K, Coulouarn C, et al. Inflammatory cytokines promote the retrodifferentiation of tumor-derived hepatocyte-like cells to progenitor cells. Hepatology. 2014;60:2077–2090.CrossRefPubMed Dubois-Pot-Schneider H, Fekir K, Coulouarn C, et al. Inflammatory cytokines promote the retrodifferentiation of tumor-derived hepatocyte-like cells to progenitor cells. Hepatology. 2014;60:2077–2090.CrossRefPubMed
10.
go back to reference Nakagawa H, Umemura A, Taniguchi K, et al. ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development. Cancer Cell. 2014;26:331–343.CrossRefPubMed Nakagawa H, Umemura A, Taniguchi K, et al. ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development. Cancer Cell. 2014;26:331–343.CrossRefPubMed
Metadata
Title
Ischemia/Reperfusion Injury and Hepatocellular Carcinoma Recurrence After Liver Transplantation: Cancer at WIT’s End?
Authors
Adrian H. Cotterell
Robert A. Fisher
Publication date
01-09-2015
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 9/2015
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-015-3729-2

Other articles of this Issue 9/2015

Digestive Diseases and Sciences 9/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.